Despite the improved sepsis mortality with the previously known hepatic protection of Ezh2 inhibitor [85], liver enzyme and bacteremia were not different from sepsis in Ezh2 control mice (Figure 7) implying a possible hepatoxicity and incomplete Ezh2 blockage of the selected inhibitor (GSK126). Here, EZH2 is linked to bacterial infectious disease with sepsis.